45 - Current Trends and Future Directions in GMP (S19E7)

Alright, so we're back for another deep dive
and today we're tackling something that's, I
don't know about you, but it's always felt kind
of like a moving target to me. Oh yeah, I know
what you mean. How do we make sure the medicines
we take, the stuff that really matters, are actually
good? How do we guarantee that quality? For sure.
It's all about good manufacturing practices or
GMPs. Right. And that's what we're diving into
today. But we're not just looking at where things
stand right now. I mean, that's important. But
we're really trying to get a glimpse into the
future. Absolutely. Where are GMPs headed? And
I think it's especially tricky because this is
such a heavily regulated field. Oh, yeah. So
how do you innovate and move forward when you've
got all these rules? That's what we're going
to try and unravel. Yeah. And it's an exciting
time to be doing that because there are some
pretty big shifts happening. Huge, right? I mean,
think about it. We've got more and more automation
coming into the picture. Robots. Exactly. Yeah.
Robots, sophisticated systems, you name it. And
then there's this whole move towards continuous
manufacturing. Which I'm still wrapping my head
around. Yeah, it's a big departure from the traditional
way of doing things. And on top of all that,
you've got these incredible advancements in therapies,
especially cell therapies. Cutting edge stuff.
Absolutely. So all of these things, they're not
just minor tweaks. They're really shaking up
how we think about GMPs. Yeah, they're forcing
us to rethink the whole thing. Exactly. And that's
what we want to unpack today. Yeah. You know,
how are these innovations changing GMP requirements?
How are the regulators adapting? What do companies
need to know? to stay compliant. How does it
impact quality systems, risk management, all
of that? So I guess the best place to start is
with these emerging trends themselves, right?
For sure. Like, let's take automation first.
I can see how You know, on the surface, it sounds
great. More efficiency, maybe fewer errors. But
when you think about it from a GMP perspective,
it kind of makes you nervous, too. Yeah. Like,
how do you make sure these automated systems
are actually doing what they're supposed to be
doing all the time, every time? Right. Right.
You can't just set it and forget it. It's not
like a Roomba. Exactly. And I think about, you
know, in some of the regulations we've looked
at, like for dietary supplements, they already
talk about the need to calibrate and check all
that equipment regularly, like in 21 CFR Part
111 .35b12. So if that's important for supplements,
imagine how much more crucial it is for actual
drug manufacturing, especially as these systems
get even more complex. Absolutely. You've got
to make sure that equipment is doing what it's
supposed to be doing consistently. It's like
your car's navigation system, right? Oh, yeah.
You've got to make sure it's accurate, up to
date, because you're relying on it to get you
where you need to go. To guide you, yeah. Exactly.
And then it's not just the physical equipment
itself, it's all the data. these systems generate.
Oh, right. Tons of it. Mountains of data, potentially.
Yeah. And that's all electronic records, which
brings in a whole other set of regulations like
21 CFR Part 11, dealing specifically with electronic
records and signatures. So it's like. The whole
digital world is colliding with GMPs. Exactly.
How do you guarantee the integrity of that digital
information? How do you make sure there's a clear
audit trail in who did what and when? These are
core GMP principles that get really interesting
when you bring in automation. So it's like GMPs
have to adapt to the digital age. Yeah, they
have to evolve. Yeah. OK, so we've talked about
automation. Let's switch gears a bit and talk
about continuous manufacturing. This one. I'll
be honest, I'm still trying to wrap my head around
it. It's a big one. It's a huge shift from how
we've traditionally made drugs, which is in batches.
Right. Make a batch, test it, release it. Exactly.
You have these distinct units. And the EAS Consulting
Group, their transcript and regulations like
21 CFR Part 211 .192, they all talk about batch
records. Yeah. So, you know, the detailed history
of each batch. Right. But with continuous manufacturing,
the process just keeps going. It never stops.
Like a river, a constant flow. Right. Raw materials
go in one end, finished product comes out the
other. So where does the idea of a batch even
fit into that? That's the million dollar question.
Yeah. If it's a continuous flow, how do you do
quality checks? If there's no clear start and
end point, how do you ensure the quality of the
product. Yeah, the traditional checkpoints just
don't seem to apply. Exactly. And this is where
the FDA's Pharmaceutical CGMPs for the 21st Century
initiative is really pushing things forward.
They're saying, look, we need to move towards
continuous real -time quality assurance. Instead
of just testing at the end of a batch, you need
to be monitoring the critical quality parameters
throughout the entire process. So it's like having
sensors all along the way. Exactly. It's like,
imagine you're cooking. OK. Instead of just tasting
the dish at the end, you have sensors in your
kitchen monitoring the temperature, the mixing
speed, everything in real time. Making sure it's
all going according to plan. Exactly. Because
if the process never stops, the quality checks
can't stop either. Makes sense. OK, so we've
covered automation, we've talked about continuous
manufacturing, and now let's jump into the deep
end with advanced therapies, especially cell
therapies. Right, diving in. This is where things
get really complex, I think. Oh, absolutely.
It's a whole different world. You know, when
you look at something like Adrian P. Gee's book
on cell therapy, CGMP facilities and manufacturing,
it really highlights the unique challenges here.
What's so different about it? Well, you're dealing
with living materials, the cells themselves.
Right. It's not just chemicals. Exactly. And
that introduces a whole new level of complexity
and variability. They were sensitive, right?
Much more sensitive. They need very specific
conditions to thrive. And the manufacturing processes
are often highly personalized, tailored to the
individual patient. So it's like personalized
medicine taken to a whole new level. Absolutely.
And you can't just treat these cells like any
other raw material. They need special handling,
specialized facilities. I was just thinking about
that. The facilities must be pretty intense.
Oh, they are. There are books like Quality Systems
and Controls for Pharmaceuticals that talk about
the need for these highly specialized production
facilities. With enhanced containment, very specific
environmental controls, rigorous safety measures.
because the risks of contamination are so much
higher with these biological materials. Yeah,
especially if you're talking about sterile products
or, you know, those that are administered in
certain ways like aerosols or powders. Exactly.
So guidelines like the CBER Compliance Program
Guidance Manual for Biological Drug Products,
those become really important here. Because they
lay out the specific requirements. Right. They
provide the roadmap for how to handle these unique
products safely and effectively. It feels like
the regulations are almost playing catch -up
though, trying to keep pace with these incredible
advancements. Yeah, there's definitely that sense
of trying to stay ahead of the curve. But I think
the FDA's pharmaceutical CGMPs for the 21st century
initiative is a good sign. How so? Well, it shows
they're recognizing that the old way of doing
things, the one -size -fits -all approach, might
not be the best way to regulate these new technologies.
They're being more flexible. Yeah, more adaptable.
They're moving towards more risk -based approaches.
It's recognizing that different products and
processes have different levels of risk. And
that makes sense. The goal is to encourage innovation
while still ensuring patient safety. delicate
balance. So it's not about stifling progress.
It's about finding a way to guide it safely.
Exactly. And this is where the concept of quality
by design or QBD comes in. Right. I've seen that
mentioned in ICH Q8 R1 and certified pharmaceutical
GMP professional handbook. Yeah. It's a big part
of the future of GMPs. It's about shifting from
just testing the end product to building quality
into the process from the very beginning. Proactive
rather than reactive. Exactly. You're using science
and risk management to design a process that
consistently delivers a high quality product.
So you understand the critical quality attributes
of your product. Right. And you design your process
to make sure those are always met. It's like
building a house. You wouldn't just build it
and then inspect it at the end. You'd make sure
the foundation is solid, the materials are strong,
all of that. You're building quality in from
the ground up. Precisely. And then you've got
process analytical technology or PACT, which
is like the eyes and ears of QBD. Oh, right.
I've heard of PIA. It's a set of tools that allow
you to monitor critical process parameters in
real time. So you can see what's happening as
it's happening. Exactly. And that lets you make
adjustments on the fly, if needed, to keep everything
within the specified parameters. Preventing problems
before they even arise. Exactly. It's all about
reducing the risks associated with manufacturing
uncertainty. So we've talked a lot about how
technology is changing the actual manufacturing
process. But what about the quality system? Ah,
yes. The backbone of GMP. Right. All those traditional
things, document control, standard operating
procedures. It's all being impacted, no doubt
about it. I mean, just think about the sheer
amount of data we were talking about earlier
with automation and continuous manufacturing.
It's overwhelming. It can be. You need a way
to manage all that information effectively. And
that's where electronic quality management systems
or EQMS come in. Right. So the good documentation
practices for electronic systems video transcript
really highlighted those. Exactly. EQMS is becoming
essential. It's about managing the entire life
cycle of electronic records, ensuring secure
audit trails, maintaining the integrity of all
that data. It's like a high -tech filing cabinet.
Exactly. But one that's completely transparent
and auditable. So everything is traceable? Precisely.
But, you know, even with all these fancy electronic
systems, good old written procedures, the SOPs,
they're still crucial. Oh, yeah. Those are the
bedrock. They really are. Devon Edwards, in his
GMP training and regulations like 21 CFR Part
111 .303, they all stress the importance of SOPs.
Standard operating procedures? Yep. They're like
the detailed instructions for everything you
do in a GMP environment, from how to operate
a piece of equipment to how to collect a sample
in the lab. You can't deviate from them, right?
Well, you can. But 21 CFR Part 211 .103 is very
clear. Any deviation has to be documented and
justified. It's like having a recipe. You got
to stick to it. Unless you have a really good
reason to change something. And you better write
that reason down. Speaking of labs, they're still
a big part of all this, right? Oh, absolutely.
They're the heart of quality control. 21 CFR,
Part 111 Subpart J, and the EAS Consulting Group
video on GMP Laboratory Overview, they spell
out all the requirements for lab operations.
Like what? Well, you need written procedures
for all the tests you do. Makes sense. Controlled
lab facilities. Right. Robust analytical processes,
scientifically sound test methods. So the methods
themselves have to be reliable. Exactly. And
that's where things like accuracy, precision,
specificity, ruggedness, all those come in. I
remember the EAS consulting group transcript
talking about this. Yeah, there are essential
characteristics of a good test method. They basically
ensure that the data you're relying on is trustworthy.
So accuracy means your results are close to the
true value. Right. Precision means you get consistent
results if you run the same test multiple times.
And specificity means the test only measures
what it's supposed to. Exactly. And ruggedness
means the test can handle small variations in
conditions and still give you reliable results.
So all of that ensures you're getting good data.
And then you have all that sophisticated equipment
in the lab. And you have to make sure it's all
working properly. Oh, yeah. That's where qualification
comes in. The DQ, IQ, OQ, PQ we talked about
earlier. Right, right. Those acronyms. Melteni
Biotech GMP 101. And the EAS consulting group
has good resources on this. Basically, you need
to make sure the equipment is suitable for its
intended purpose and functions correctly. And
that involves checking the design, installation,
operation, performance. Right, all of that. And
then, of course, regular calibration is essential,
too. So with all these moving parts, it seems
like risk management is becoming even more crucial
in the pharmaceutical industry. Oh, absolutely.
It's moving front and center. The more complex
these processes get, the more important it becomes
to have a really solid approach to managing risks.
And we have a framework for that, right? We do.
ICH Q9, the guideline on quality risk management,
and the FDA has adopted it. as mentioned in quality
risk management in the FDA -regulated industry.
It's all about proactively identifying, assessing,
and controlling potential risks to both product
quality and patient safety. So it's not just
about reacting to problems after they happen.
Nope. It's about anticipating what could go wrong
and putting measures in place to prevent it or
at least minimize the impact. And it seems like
these risk management principles are being applied
across the entire life cycle of a drug now. Exactly.
From early development to manufacturing, distribution,
even inspections. It's a holistic approach to
ensuring quality and safety. And one of the things
I've been hearing a lot about is contamination
control strategies. Oh yeah, that's a big one.
Especially with the revised EU -GMP Annex 1,
which they talk about in the Risk Revolution
video. Contamination control is no longer just
a nice -to -have, it's a formal, documented requirement.
So you need a comprehensive plan. Exactly. It's
not just scattered procedures anymore. It's a
cohesive strategy outlining how you're going
to prevent contamination at every stage. Especially
for those high risk products. Absolutely. The
ones where contamination could have serious consequences.
And it seems like tools from other industries
are finding their way into pharma like hazard
analysis and critical control points or HACCP.
Yeah. HACCP is a great example. It's a systematic
way to identify and control hazards and quality
risk management in the FDA. regulated industry
really dives into how it can be applied to pharmaceuticals.
So it's not just about contamination, it's about
any hazard that could impact quality or safety.
Exactly. And then there's KPA corrective and
preventive action, which is all about learning
from your mistakes and preventing them from happening
again. It's the engine of continuous improvement.
It really is. The Rodriguez -Perez book on KPA
is a great resource for understanding how to
build a strong KPA system. So with all these
changes happening, what can companies do to keep
up. How can they adapt to all these technological
advancements and evolving regulations while still
staying compliant with GMPs? It's a challenge,
for sure. But I think continuous learning is
key. Devon Edwards talks a lot about this in
his training. Training for everyone involved.
Exactly. Everyone needs to be up to speed on
the latest technologies and the latest GMP requirements.
It's about creating a culture of ongoing learning.
And documentation, of course, is more important
than ever. Oh, absolutely. And it's not just
about paper anymore. We're moving towards more
and more electronic documentation. Right. But
the principles of good documentation practices,
or GDOCP, those still apply. So the LCOA principles,
right? Exactly. Attributable, legible, contemporaneous,
original, and accurate. Those are still the gold
standard. Whether it's on paper or in a computer
system, those principles have to be upheld. And
strong process controls are crucial, too, from
start to finish. Absolutely. 21 CFR Part 211
Subpart F and 21 CFR 211 .101. They lay out the
requirements for process controls. It's all about
making sure things are done right, consistently,
to prevent errors and ensure quality. And when
things do go wrong, thorough investigations are
essential. Absolutely. 21 CFR Part 211 .192 and
Bliesner's book, Establishing a CGMP Laboratory
Audit System, they provide a lot of guidance
on investigations. You have to figure out what
happened, why it happened, and whether it could
happen again. Or whether it affected other batches
or products. Right. It's about getting to the
root cause and taking steps to prevent recurrence.
It also seems like keeping up with the regulatory
landscape itself is becoming a full -time job.
It really is. Regulatory intelligence is so important
now. Companies need to be actively monitoring
what the FDA and other agencies are doing, what
new guidances are coming out, what changes are
on the horizon. So they can be prepared. Exactly.
And it's not just about reacting to new regulations,
it's about being proactive and anticipating what's
coming. It's a lot to keep track of. It is. But
it's all in service of a really important goal,
making sure the medicines we rely on are safe
and effective. And as technology keeps advancing,
I think it's only going to get more complex.
Oh, yeah. The pace of innovation is incredible.
But that's also what makes it so exciting. It's
a challenge, but it's a challenge worth tackling.
Absolutely. And for anyone listening who wants
to dive deeper into any of this, I'd encourage
you to check out the specific regulations and
guidances we've mentioned. Like 21 CFR parts,
11, 111, 211. Those are good starting points.
And ICH Q9, the EUGMP Annex 1, those are great
resources, too. There's a wealth of information
out there. And it's constantly evolving, so it's
important to stay up to date. Absolutely. You
guys stay curious and keep learning. That's the
key to success in this field. Well said. All
right. That's another deep dive wrapped up. Thanks
for joining us. Thanks for having me. And we'll
see you next time for another fascinating exploration
of, well, who knows what. That's the fun of it.
The world of knowledge awaits. Exactly. See ya.